Literature DB >> 20535626

Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy.

Chems Gharbi1, Edward Bourry, Philippe Rouvier, Sabria Hacini, Ahmed Letaief, Alain Baumelou, Hassane Izzedine.   

Abstract

Although uncommon, thrombotic microangiopathy (TMA) is one of the most serious complications in patients with systemic lupus erythematosus. A 30-year-old black woman admitted to our hospital because of fever, fatigue, 'dark' urine and rapidly progressive renal failure was found to have systemic lupus erythematous and atypical hemolytic uremic syndrome. Kidney biopsy showed WHO class IV lupus nephritis with crescents and TMA. Hemodialysis was initiated for worsening renal failure. The patient was treated with corticosteroids, monthly pulse intravenous Cyclophosphamide, plasmapheresis and Rituximab on a weekly basis for 4 weeks. The patient's blood pressure was aggressively controlled using antihypertensive agents. Despite this extensive therapy, she remained dialysis dependent although hematological parameters returned to normal values.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535626     DOI: 10.1007/s10157-010-0300-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  32 in total

1.  Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: Distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome.

Authors:  Sylvia Dold; Ranju Singh; Haroon Sarwar; Yamini Menon; Liliana Candia; Luis R Espinoza
Journal:  Arthritis Rheum       Date:  2005-12-15

2.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

3.  Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood.

Authors:  H I Brunner; M Freedman; E D Silverman
Journal:  Arthritis Rheum       Date:  1999-11

4.  "Pauci-Immune" proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome.

Authors:  D A Charney; G Nassar; L Truong; T Nadasdy
Journal:  Am J Kidney Dis       Date:  2000-06       Impact factor: 8.860

Review 5.  Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case and review.

Authors:  A Sakarcan; J Stallworth
Journal:  Pediatr Nephrol       Date:  2001-08       Impact factor: 3.714

6.  Recurrent thrombotic thrombocytopenic purpura in a young boy with systemic lupus erythematosus.

Authors:  Lai-kei Yuen; Wai-ming Lai; Pak-chiu Tong; Wing-tat Poon; Kei-chiu Tse; Man-chun Chiu
Journal:  J Clin Rheumatol       Date:  2007-08       Impact factor: 3.517

7.  Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus.

Authors:  T Tsumagari; S Fukumoto; M Kinjo; K Tanaka
Journal:  Hum Pathol       Date:  1985-01       Impact factor: 3.466

8.  Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome.

Authors:  Feng Yu; Ying Tan; Ming-Hui Zhao
Journal:  Nephrol Dial Transplant       Date:  2009-08-23       Impact factor: 5.992

9.  Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL).

Authors:  G Banfi; T Bertani; V Boeri; T Faraggiana; G Mazzucco; G Monga; G Sacchi
Journal:  Am J Kidney Dis       Date:  1991-08       Impact factor: 8.860

10.  Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties.

Authors:  Ami A Shah; John P Higgins; Eliza F Chakravarty
Journal:  Nat Clin Pract Rheumatol       Date:  2007-06
View more
  5 in total

1.  Eculizumab in secondary atypical haemolytic uraemic syndrome.

Authors:  Teresa Cavero; Cristina Rabasco; Antía López; Elena Román; Ana Ávila; Ángel Sevillano; Ana Huerta; Jorge Rojas-Rivera; Carolina Fuentes; Miquel Blasco; Ana Jarque; Alba García; Santiago Mendizabal; Eva Gavela; Manuel Macía; Luis F Quintana; Ana María Romera; Josefa Borrego; Emi Arjona; Mario Espinosa; José Portolés; Carolina Gracia-Iguacel; Emilio González-Parra; Pedro Aljama; Enrique Morales; Mercedes Cao; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

Review 2.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

3.  Pathological severity determines the renal recovery for anti-myeloperoxidase antibody-associated vasculitis requiring dialysis at disease onset: a retrospective study.

Authors:  Peng-Cheng Xu; Tong Chen; Si-Jing Wu; Xia Yang; Shan Gao; Shui-Yi Hu; Li Wei; Tie-Kun Yan
Journal:  BMC Nephrol       Date:  2019-07-30       Impact factor: 2.388

4.  Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.

Authors:  Monika Vitkauskaitė; Artūras Vinikovas; Marius Miglinas; Laurynas Rimševičius; Agnė Čerkauskaitė; Ernesta Mačionienė; Eglė Ašakienė
Journal:  Clin Case Rep       Date:  2022-03-15

5.  Thrombotic microangiopathy in a patient with systemic lupus erythematosus and anti-factor H autoantibodies.

Authors:  Cátia Raquel Figueiredo; Rachele Escoli; Paulo Santos; Flora Sofia; Karina Lopes
Journal:  CEN Case Rep       Date:  2021-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.